Low Serum Level α-Synuclein and Tau Protein in Autism Spectrum Disorder Compared to Controls

Neuropediatrics

Volumn 46, Issue 6, 2015, Pages 410-415

  Kadak, Muhammed Tayyib ^a   Cetin, Ihsan ^b   Tarakçloʇlu, Mahmut Cem ^c   Özer, Ömer Faruk ^d   Kaçar, Selma ^a   Çimen, Behzat ^e  

^a ISTANBUL UNIVERSITY   (Turkey)

^b BATMAN UNIVERSITY   (Turkey)

^c Educational Hospital   (Turkey)

^d Bezmialem Vaklf University   (Turkey)

^e ERCIYES UNIVERSITY   (Turkey)

Author keywords

autism; synucleinopathy; tau; synuclein

Indexed keywords

ALPHA SYNUCLEIN; TAU PROTEIN;

ARTICLE; AUTISM; AUTISM ASSESSMENT; CHILD; CHILDHOOD AUTISM RATING SCALE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; HUMAN; MALE; MICROGLIA; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN BLOOD LEVEL; RATING SCALE; BLOOD; CASE CONTROL STUDY; PRESCHOOL CHILD;

ALPHA-SYNUCLEIN; AUTISM SPECTRUM DISORDER; CASE-CONTROL STUDIES; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; MALE; TAU PROTEINS;

EID: 84948117648     PISSN: 0174304X     EISSN: 14391899     Source Type: Journal    
DOI: 10.1055/s-0035-1565273     Document Type: Article

References (38)

1. Mollenhauer B., Locascio J. J., Schulz-Schaeffer W., Sixel-Döring F., Trenkwalder C., Schlossmacher M. G. α-Synuclein and tau concentrations in cerebrospinal fluid of patients presenting with parkinsonism: a cohort study. Lancet Neurol: 2011; 10 3 230 240
2. Sengupta U., Guerrero-Muñoz M. J., Castillo-Carranza D. L., et al. Pathological interface between oligomeric alpha-synuclein and tau in synucleinopathies. Biol Psychiatry: 2015;;pii:S0006-3223(15)00003-00007. doi:10.1016/j.biopsych.2014.12.019
3. Sui Y. T., Bullock K. M., Erickson M. A., Zhang J., Banks W. A. Alpha synuclein is transported into and out of the brain by the blood-brain barrier. Peptides: 2014; 62 197 202
4. Cheng F., Vivacqua G., Yu S. The role of α-synuclein in neurotransmission and synaptic plasticity. J Chem Neuroanat: 2011; 42 4 242 248
5. El-Agnaf O. MA, Irvine G. B. Review: formation and properties of amyloid-like fibrils derived from alpha-synuclein and related proteins. J Struct Biol: 2000; 130 2-3 300 309
6. Lee P. H., Lee G., Park H. J., Bang O. Y., Joo I. S., Huh K. The plasma alpha-synuclein levels in patients with Parkinson's disease and multiple system atrophy. J Neural Transm: 2006; 113 10 1435 1439
7. Duran R., Barrero F. J., Morales B., Luna J. D., Ramirez M., Vives F. Plasma alpha-synuclein in patients with Parkinson's disease with and without treatment. Mov Disord: 2010; 25 4 489 493
8. Li Q. X., Mok S. S., Laughton K. M., et al. Plasma alpha-synuclein is decreased in subjects with Parkinson's disease. Exp Neurol: 2007; 204 2 583 588
9. Hong Z., Shi M., Chung K. A., et al. DJ-1 and alpha-synuclein in human cerebrospinal fluid as biomarkers of Parkinson's disease. Brain: 2010; 133 (Pt 3): 713 726
10. Miller D. W., Hague S. M., Clarimon J., et al. Alpha-synuclein in blood and brain from familial Parkinson disease with SNCA locus triplication. Neurology: 2004; 62 10 1835 1838
11. Desplats P., Lee H. J., Bae E. J., et al. Inclusion formation and neuronal cell death through neuron-to-neuron transmission of alpha-synuclein. Proc Natl Acad Sci U S A: 2009; 106 31 13010 13015
12. Roy B., Jackson G. R. Interactions between tau and α-synuclein augment neurotoxicity in a drosophila model of Parkinson's disease. Hum Mol Genet: 2014; 23 11 3008 3023
13. Parellada M., Penzol M. J., Pina L., et al. The neurobiology of autism spectrum disorders. Eur Psychiatry: 2014; 29 1 11 19
14. Schulz-Schaeffer W. J. The synaptic pathology of alpha-synuclein aggregation in dementia with Lewy bodies, Parkinson's disease and Parkinson's disease dementia. Acta Neuropathol: 2010; 120 2 131 143
15. Kramer M. L., Schulz-Schaeffer W. J. Presynaptic alpha-synuclein aggregates, not Lewy bodies, cause neurodegeneration in dementia with Lewy bodies. J Neurosci: 2007; 27 6 1405 1410
16. Nikolaus S., Antke C., Müller H. W. In vivo imaging of synaptic function in the central nervous system: I. Movement disorders and dementia. Behav Brain Res: 2009; 204 1 1 31
17. Shipton O. A., Leitz J. R., Dworzak J., et al. Tau protein is required for amyloid beta-induced impairment of hippocampal long-term potentiation. J Neurosci: 2011; 31 5 1688 1692
18. Pozueta J., Lefort R., Shelanski M. L. Synaptic changes in Alzheimer's disease and its models. Neuroscience: 2013; 251 51 65
19. Baykara B., Gencer Ö, ̄lkin Z., Miral S. Neurocognitive features of the frontal lobe in parents of autistic children [in Turkish]. Turk Psikiyatri Derg: 2008; 19 3 225 234
20. Borghi R., Marchese R., Negro A., et al. Full length alpha-synuclein is present in cerebrospinal fluid from Parkinson's disease and normal subjects. Neurosci Lett: 2000; 287 1 65 67
21. El-Agnaf O. M., Salem S. A., Paleologou K. E., et al. Alpha-synuclein implicated in Parkinson's disease is present in extracellular biological fluids, including human plasma. FASEB J: 2003; 17 13 1945 1947
22. Totterdell S., Meredith G. E. Localization of alpha-synuclein to identified fibers and synapses in the normal mouse brain. Neuroscience: 2005; 135 3 907 913
23. Chandra S., Gallardo G., Fernández-Chacón R., Schlüter O. M., Südhof T. C. Alpha-synuclein cooperates with CSPalpha in preventing neurodegeneration. Cell: 2005; 123 3 383 396
24. Fortin D. L., Troyer M. D., Nakamura K., Kubo S., Anthony M. D., Edwards R. H. Lipid rafts mediate the synaptic localization of alpha-synuclein. J Neurosci: 2004; 24 30 6715 6723
25. Jo E., Darabie A. A., Han K., Tandon A., Fraser P. E., McLaurin J. alpha-Synuclein-synaptosomal membrane interactions: implications for fibrillogenesis. Eur J Biochem: 2004; 271 15 3180 3189
26. Di Rosa G., Puzzo D., Sant'Angelo A., Trinchese F., Arancio O. Alpha-synuclein: between synaptic function and dysfunction. Histol Histopathol: 2003; 18 4 1257 1266
27. Liu S., Ninan I., Antonova I., et al. alpha-Synuclein produces a long-lasting increase in neurotransmitter release. EMBO J: 2004; 23 22 4506 4516
28. Al-Wandi A., Ninkina N., Millership S., Williamson S. J., Jones P. A., Buchman V. L. Absence of alpha-synuclein affects dopamine metabolism and synaptic markers in the striatum of aging mice. Neurobiol Aging: 2010; 31 5 796 804
29. Lotharius J., Brundin P. Impaired dopamine storage resulting from alpha-synuclein mutations may contribute to the pathogenesis of Parkinson's disease. Hum Mol Genet: 2002; 11 20 2395 2407
30. Sidhu A., Wersinger C., Vernier P. Does alpha-synuclein modulate dopaminergic synaptic content and tone at the synapse? FASEB J: 2004; 18 6 637 647
31. Yavich L., Tanila H., Vepsäläinen S., Jäkälä P. Role of alpha-synuclein in presynaptic dopamine recruitment. J Neurosci: 2004; 24 49 11165 11170
32. Hutsler J. J., Zhang H. Increased dendritic spine densities on cortical projection neurons in autism spectrum disorders. Brain Res: 2010; 1309 83 94
33. Nguyen M., Roth A., Kyzar E. J., et al. Decoding the contribution of dopaminergic genes and pathways to autism spectrum disorder (ASD). Neurochem Int: 2014; 66 15 26
34. Garber K. Neuroscience. Autism's cause may reside in abnormalities at the synapse. Science: 2007; 317 5835 190 191
35. Zoghbi H. Y. Postnatal neurodevelopmental disorders: meeting at the synapse? Science: 2003; 302 5646 826 830
36. Morgan J. T., Chana G., Pardo C. A., et al. Microglial activation and increased microglial density observed in the dorsolateral prefrontal cortex in autism. Biol Psychiatry: 2010; 68 4 368 376
37. Scarr E., Dean B. Altered neuronal markers following treatment with mood stabilizer and antipsychotic drugs indicate an increased likelihood of neurotransmitter release. Clin Psychopharmacol Neurosci: 2012; 10 1 25 33
38. Chadchankar H., Yavich L. Sub-regional differences and mechanisms of the short-term plasticity of dopamine overflow in striatum in mice lacking alpha-synuclein. Brain Res: 2011; 1423 67 76